Sen. David Vitter challenges FDA over breast cancer drug ruling
The FDA says it hasn't found evidence that the benefits of Avastin outweigh potential side effects

FDA Pulls Approval Of Avastin For Breast Cancer
After more than a year of deliberations and an unprecedented public hearing in June, the agency has revoked approval of the biotech blockbuster Avastin, a medicine that chokes off the blood supply to various cancer cells, as a treatment for metastatic breast cancer.

FDA Did the Right Thing in Pulling Avastin for Breast Cancer
If you want the FDA to approve more innovative, new drugs based on promising but early clinical results, you have to give the FDA a way to revoke those approvals later on, should larger trials prove that those drugs aren t as safe or effective as they first seemed. This is why the FDA should be congratulated for the way it has handled the Avastin breast cancer saga, and why I hope we will see ...